Company intelligence / Profile preview

NÀU

Seattle, Washington, United Statesdreamfiction.fandom.com ↗

Ownership: Private
Development stage: Other

Overview

Nautilus Biotechnology has developed a next-generation proteomics platform designed to radically improve the scale and accessibility of protein quantification. The company's technology integrates high-resolution optical imaging with advanced fluidics and proprietary multi-affinity probes to enable deep profiling of the human proteome. As a development-stage company, it has not yet reported clinical results but aims to democratize access to comprehensive protein data for biomedical research and drug discovery.

Modalities: Device (Proteome analysis system)Reagent kit (multi-affinity probe reagents)Software (bioinformatics/proteomics analysis)Platform technology (proteomics platform)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on NÀU.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NÀU.

Explore the full profile